Viking Therapeutics (VKTX) Notes Payables (2014 - 2018)

Viking Therapeutics has reported Notes Payables for 5 years, with the latest figure at $3.7 million in Q1 2018.

• Quarterly Notes Payables changed N/A year-over-year to $3.7 million in Q1 2018, while the trailing twelve-month figure through Mar 2018 was $3.7 million (changed N/A YoY) and the FY2017 annual result came in at $3.5 million, up 5.55% from the prior year.
• Notes Payables climbed to $3.7 million in Q1 2018 per VKTX's latest filing, from $3.5 million in the prior quarter.
• Over five years, Notes Payables peaked at $3.7 million in Q1 2018 and troughed at $304274.0 in Q4 2014.
• A 5-year average of $2.4 million and a median of $2.8 million in 2016 frame the typical range for Notes Payables.
• The sharpest annual moves came in 2016 and 2017: Notes Payables jumped 47.89% in 2016, then gained 5.55% in 2017.
• Over 5 years, Notes Payables stood at $304274.0 in 2014, then soared by 528.06% to $1.9 million in 2015, then surged by 71.09% to $3.3 million in 2016, then grew by 5.55% to $3.5 million in 2017, then grew by 7.82% to $3.7 million in 2018.
• According to Business Quant data, Notes Payables over the past three periods registered $3.7 million, $3.5 million, and $3.2 million for Q1 2018, Q4 2017, and Q3 2017 respectively.